EUCTR2006-002992-42-IT进行中（未招募）不适用
A phase II study to evaluate the efficacy of bevacizumab in combination with capecitabine and concomitant radiotherapy in patients affected by non-resectable locally advanced pancreatic cancer. - GP06
AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO0 个研究点开始时间: 2007年7月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Age 18-75;
- •-Zubrod Performance status 0-1;
- •-Histologically confirmed locally advanced pancreatic cancer.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Brain or visceral metastasis;
- •-Prior radiotherapy or chemotherapy within 5 years.
研究者
相似试验
进行中（未招募）
不适用
A single arm, open-label, phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of patients with HER2-positive locally recurrent or metastatic breast cancerHER2-positive locally recurrent or metastatic breast cancer.MedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerMedDRA version: 9.1Level: LLTClassification code 10006198Term: Breast cancer recurrentEUCTR2008-003283-20-SKF. Hoffmann-La Roche Ltd88
进行中（未招募）
不适用
A study of bevacizumab in combination with trastuzumab and capecitabine in patients with breast cancer that recurred at/near the same place as the original tumour or that spread to other non-adjacent tissuesHER2-positive locally recurrent or metastatic breast cancer.MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006198Term: Breast cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-003283-20-DKF. Hoffmann-La Roche Ltd88
进行中（未招募）
不适用
A study of bevacizumab in combination with trastuzumab and capecitabine in patients with breast cancer that recurred at/near the same place as the original tumour or that spread to other non-adjacent tissuesHER2-positive locally recurrent or metastatic breast cancer.MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006198Term: Breast cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-003283-20-SEF. Hoffmann-La Roche Ltd88
进行中（未招募）
不适用
A single arm, open-label, phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of patients with HER2-positive locally recurrent or metastatic breast cancerEUCTR2008-003283-20-FRF. Hoffmann-La Roche Ltd88
进行中（未招募）
不适用
A pilot phase II study to assess the efficacy of Brentuximab Vedotin administered sequentally with ABVD chemotherapy in patients with untreated Hodgkin LymphomaEUCTR2012-002012-46-ITAZIENDA OSPEDALIERA POLICLINICO DI MODENA